Cargando…

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypoglycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yaribeygi, Habib, Maleki, Mina, Jamialahmadi, Tannaz, Moallem, Seyed Adel, Sahebkar, Amirhossein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Leibniz Research Centre for Working Environment and Human Factors 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10279968/ https://www.ncbi.nlm.nih.gov/pubmed/37346806 http://dx.doi.org/10.17179/excli2023-6022

Ejemplares similares

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art
por: Yaribeygi, Habib, et al.
Publicado: (2023)

Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Increases Antioxidative Capacity and Improves Renal Function in Diabetic Rats
por: Yaribeygi, Habib, et al.
Publicado: (2023)

Molecular Mechanisms by Which Imeglimin Improves Glucose Homeostasis
por: Yaribeygi, Habib, et al.
Publicado: (2020)

Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
por: Yaribeygi, Habib, et al.
Publicado: (2022)

Pathophysiology of Physical Inactivity-Dependent Insulin Resistance: A Theoretical Mechanistic Review Emphasizing Clinical Evidence
por: Yaribeygi, Habib, et al.
Publicado: (2021)

Antioxidative Potentials of Incretin-Based Medications: A Review of Molecular Mechanisms
por: Yaribeygi, Habib, et al.
Publicado: (2021)

Impact of Incretin-Based Therapies on Adipokines and Adiponectin
por: Yaribeygi, Habib, et al.
Publicado: (2021)

The Impact of Incretin-Based Medications on Lipid Metabolism
por: Yaribeygi, Habib, et al.
Publicado: (2021)

Molecular mechanisms linking stress and insulin resistance
por: Yaribeygi, Habib, et al.
Publicado: (2022)

Brain insulin signaling and cognition: Possible links
por: Yaribeygi, Habib, et al.
Publicado: (2023)

The Impact of Diabetes Mellitus in COVID-19: A Mechanistic Review of Molecular Interactions
por: Yaribeygi, Habib, et al.
Publicado: (2020)

Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus
por: Yaribeygi, Habib, et al.
Publicado: (2021)

The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Dipeptydilpeptidase-4 Inhibitors on Blood Pressure and Cardiovascular Complications in Diabetes
por: Yaribeygi, Habib, et al.
Publicado: (2021)

The Predictive Role of Parathyroid Hormone for Nonalcoholic Fatty Liver Disease following Bariatric Surgery
por: Jamialahmadi, Tannaz, et al.
Publicado: (2022)

Association of C-reactive protein with histological, elastographic, and sonographic indices of non-alcoholic fatty liver disease in individuals with severe obesity
por: Jamialahmadi, Tannaz, et al.
Publicado: (2023)

Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis
por: Akbari, Abolfazl, et al.
Publicado: (2022)

Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis
por: Mahmoudi, Ali, et al.
Publicado: (2021)

The Emerging Role of Nanomedicine in the Management of Nonalcoholic Fatty Liver Disease: A State-of-the-Art Review
por: Moosavian, Seyedeh Alia, et al.
Publicado: (2021)

The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
por: Patel, Dhiren K., et al.
Publicado: (2019)

Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients
por: Xiang, Boyang, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)

Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Effect of Curcumin on Attenuation of Liver Cirrhosis via Genes/Proteins and Pathways: A System Pharmacology Study
por: Mahmoudi, Ali, et al.
Publicado: (2022)

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
por: Liu, Zhenghong, et al.
Publicado: (2021)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Clinical Benefits of Sodium–Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects
por: Kubota, Yoshiaki, et al.
Publicado: (2022)

Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure
por: Chen, KangYu, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter (SGLT2) inhibitors: A new Era in renovascular protection
por: Berbari, Adel E.
Publicado: (2020)

Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review
por: Georgiou, Petros, et al.
Publicado: (2021)

The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors – Real-World Data
por: Gallwitz, Baptist
Publicado: (2018)

Lowering the risk of gout: Another benefits from the use of sodium–glucose cotransporter 2 inhibitors
por: Sheu, Wayne H‐H
Publicado: (2020)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
por: Cavaiola, Tricia Santos, et al.
Publicado: (2018)

Hemodynamic Effects of Sodium-Glucose Cotransporter 2 Inhibitors
por: Sano, Motoaki
Publicado: (2017)

Sodium-glucose cotransporter inhibitors: beyond glycaemic control
por: Vergara, Ander, et al.
Publicado: (2019)

Renal outcomes with sodium-glucose cotransporters 2 inhibitors
por: Sun, Xiaoya, et al.
Publicado: (2022)

Effect of Bariatric Surgery on Flow-Mediated Vasodilation as a Measure of Endothelial Function: A Systematic Review and Meta-Analysis
por: Jamialahmadi, Tannaz, et al.
Publicado: (2022)

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
por: Tang, Jun, et al.
Publicado: (2022)

Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease
por: Dokmak, Amr, et al.
Publicado: (2019)

The Possible Mechanisms for Improvement of Liver Function due to Sodium-Glucose Cotransporter-2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e9krbqk1gr7m5e50gd021btpo3